A clinical trial led by researchers at Dana-Farber Cancer Institute tested a vitamin D receptor (VDR) modulation strategy intended to alter the tumor microenvironment in pancreatic cancer. The study, published May 25, 2026 in Nature Cancer, focuses on using VDR pathway manipulation to counter resistance mechanisms that often limit responses to conventional therapy. The work traces the concept to the Salk Institute, where researchers previously explored how adjusting VDR activity can reshape immune and stromal interactions inside tumors. Pancreatic cancer has remained difficult to treat largely due to dense, therapy-resistant tumor biology. If the trial’s findings continue to demonstrate clinically meaningful effects—particularly in biomarker-defined subgroups—it could support further development of VDR-targeted approaches either as monotherapy in select settings or as combination strategies with standard regimens.